Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Multiple Myeloma
Multiple Myeloma
,
Multiple Myeloma
,
Multiple Myeloma
Pomalidomide a Promising New Immunomodulatory Drug for Multiple Myeloma
Play Video
Multiple Myeloma
Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma
Wayne Kuznar
Play Video
Multiple Myeloma
Pomalidomide plus Low-Dose Dexamethasone Combination Likely to Be Cost-Effective
Play Video
Multiple Myeloma
Pomalidomide Shows Strong Activity in Relapsed/Refractory Myeloma
Caroline Helwick
Play Video
Multiple Myeloma
Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Play Video
Multiple Myeloma
The Evolution of Survivorship Care in Multiple Myeloma
John A. Welz, MPH
Play Video
Multiple Myeloma
Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Play Video
Multiple Myeloma
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Play Video
Breast Cancer
,
FDA Approvals
,
In the News
,
Multiple Myeloma
,
Pediatric Cancer
,
Select Drug Profiles
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Play Video
Multiple Myeloma
,
Multiple Myeloma
VISTA Final Analysis Upholds Survival Benefit of Bortezomib at 5 Years
Caroline Helwick
,
Caroline Helwick
Play Video
2
3
4
5
6
Page 5 of 6
Results 41 - 50 of 52